千红制药 (002550)
Changzhou Qianhong Bio-pharma Co.,Ltd
K-Line Chart
No K-line data available
Company NameChangzhou Qianhong Bio-Pharmaceutical Co., Ltd.
Listing Date2011-02-18
Issue Price32RMB
Registered Capital12798010k RMB
Legal RepresentativeWang Ke
Registered AddressNo. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province
IndustryChemical Pharmaceuticals
Main BusinessProduction and sales of pharmaceuticals [limited to tablets, hard capsules, granules, active pharmaceutical ingredients (APIs), lyophilized powder, lyophilized powder injections (including anti-tumor drugs), small-volume injections (including non-terminally sterilized and pre-filled syringes)] and diagnostic testing reagents (excluding those requiring pre-approval); purchase of agricultural and sideline products (except for special regulations); leasing of own facilities; import and export business of various commodities and technologies (excluding those restricted or prohibited by the state).
Company ProfileChangzhou Qianhong Bio-Pharmaceutical Co., Ltd. was established on April 30, 2003, with its registered address at No. 518 Yunhe Road, Xinbei District, Changzhou City. The legal representative is Wang Yaofang. Its business scope includes the production and sales of pharmaceuticals [limited to tablets, hard capsules, granules, active pharmaceutical ingredients (APIs), lyophilized powder, lyophilized powder injections (including anti-tumor drugs), small-volume injections (including non-terminally sterilized and pre-filled syringes)] and diagnostic testing reagents (excluding those requiring pre-approval); purchase of agricultural and sideline products (except for special regulations); leasing of own facilities; import and export business of various commodities and technologies (excluding those restricted or prohibited by the state). (Projects subject to approval by law can only be carried out after approval by relevant departments.) Changzhou Qianhong Bio-Pharmaceutical Co., Ltd. has invested in 6 companies.
Stock Details
1. Key Indicators
- Total Shares(W): 127980.00
- Circulating A-Shares(W): 94124.02
- Earnings Per Share(RMB): 0.3066
- Net Assets Per Share(RMB): 2.1494
- Operating Revenue(W RMB): 121501.50
- Total Profit(W RMB): 43779.87
- Net Profit Attributable to Parent(W RMB): 38322.63
- Net Profit Growth Rate(%): 23.79
- Weighted Return on Equity(%): 14.5000
- Operating Cash Flow Per Share(RMB): 0.2280
- Undistributed Profit Per Share(RMB): 0.9965
- Capital Reserve Per Share(RMB): 0.0324
2. Main Business
The main business covers:
- Drug production, contract production, wholesale, retail, import and export.
- Technology import/export and agency.
- Medical packaging material manufacturing.
- Primary agricultural product procurement.
- Technical services, development, consultation, exchange, transfer, and promotion.
- Information consulting services.
- Non-residential real estate leasing and housing leasing.
3. Company Basic Information
- Company Name: Changzhou Qianhong Biopharma Co., Ltd.
- Listing Date: 2011-02-18
- Industry: Pharmaceutical Manufacturing
- Address: No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province, China
- Website: www.qhsh.com.cn
- Company Profile: Changzhou Qianhong Biopharma Co., Ltd. was established through the overall change of Changzhou Qianhong Biopharma Co., Ltd. The company completed its industrial and commercial registration with the Changzhou Administration for Market Regulation in Jiangsu Province on March 15, 2008.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 4903.52 | 5.21 |
| 2 | Ping An Securities - Zhou Guanxin - Ping An Securities Xin Chuang No. 50 Single Asset Management Plan | Asset Management Plan | 1947.69 | 2.07 |
| 3 | CCB Fund - Zhao Renyi - CCB Xin Xiang No.1 Single Asset Management Plan | Asset Management Plan | 1400.00 | 1.49 |
| 4 | Bodo CSI 1000 Index Enhanced Securities Investment Fund Class A | Fund | 31.17 | 0.03 |
5. Concept Sectors
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Employee Stock Ownership
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information